Disease Information & Support

www.lls.org/diseaseinformation

The Word:

donate

Generic name Tretinoin
Pronunciation TREH-ti-noyn
Brand name(s), other common name(s) Vesanoid®, ATRA
Drug type  Cell-maturing agent
How the drug is given By mouth

Tretinoin is an FDA-approved drug that is used to induce remission in patients who have acute promyelocytic leukemia (APL, also known as "M3 AML"), a type of acute myeloid leukemia (AML), with the t(15;17) translocation and/or the presence of the PML-RARa gene and who are intolerant of, refractory to, or have relapsed from anthracycline-based chemotherapy.

Side effects needing medical attention: Difficulty in breathing or rapid breathing; wheezing; unexplained fever; weight gain or weight loss; dizziness; fainting; bone pain; discomfort or pain in chest or feeling of heaviness in chest; convulsions or seizures; difficulty speaking, slow speech or inability to speak; inability to move arms, legs or muscles of face; pain in back of left arm; unusual bleeding; blood in urine; cough; headache; joint pain; sores in mouth or on lips, or pain or sores in mouth or nose; changes in vision; coughing; sore throat; decreased urination; earache or feeling of fullness in ear; irregular heartbeat; depression or other mood, mental or personality changes; rash; swelling of abdomen, face, fingers, hands, feet or lower legs; cramping or pain in stomach (severe); difficult or painful urination; drowsiness (severe and continuing); pain in lower back or side; yellow eyes or skin; weakness and fatigue; nausea and vomiting; increased sweating; anxiety; confusion; constipation; diarrhea; dryness of skin, mouth or nose or cracked lips; feeling of burning, crawling or tingling in skin; flushing; general feeling of illness; indigestion; loss of appetite; shivering; trouble sleeping.

 

For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Tuesday, October 16, 2012